Discovery of Pyrazole-Based Positron Emission Tomography Agent that Maps Histone Deacetylase 6 (HDAC6) in the Nonhuman Primate Brain
- J Med Chem. 2025 Nov 13;68(21):23375-23388. doi: 10.1021/acs.jmedchem.5c02216.
- 1. National Institute for Quantum Science and Technology, Inage-ku, Chiba 263-8555, Japan.
- 2. Takeda Pharmaceutical Company Limited, Fujisawa, Kanagawa 251-8555, Japan.
- 3. Takeda Pharmaceutical Company Limited, Chuo-ku, Osaka 540-8645, Japan.
- 4. Takeda Development Center Americas, Inc., Cambridge, Massachusetts 02142, United States.
- 5. Axcelead Drug Discovery Partners, Inc., Fujisawa, Kanagawa 251-0012, Japan.
Histone deacetylase 6 (HDAC6) is a crucial target for the development of pharmaceuticals used in the treatment of neurodegenerative disorders. Here, we identified 16a as a candidate of positron emission tomography (PET) tracer for HDAC6 imaging from pyrazole derivatives, which showed strong HDAC6 affinity (Kd = 1.66 nM) and higher accumulation in the brain of wild-type mice than in HDAC6 knockout mice. Following radiolabeling with fluorine-18, PET with [18F]16a exhibited heterogeneous uptake of radioactivity, corresponding to the biological distribution of HDAC6 in the monkey brain. These radioactive distributions were homogeneously diminished by the preadministration of ACY-775, a potent inhibitor of HDAC6, suggesting that radioactive accumulation in PET images could reflect the specific binding of [18F]16a with HDAC6. Thus, [18F]16a is a promising PET tracer for HDAC6 imaging that motivates future clinical research.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: HDACResearch Areas: Neurological Disease